| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
From the Departments of Pathology and Laboratory Medicine,* Medicine, Urology, and Division of Biostatistics, ¶ Indiana University School of Medicine, Indianapolis, Indiana; and MedImmune Inc., Gaithersburg, Maryland
EphA2 is a transmembrane receptor tyrosine kinase that is overexpressed in many carcinomas. Specific targeting of EphA2 with monoclonal antibodies is sufficient to inhibit the growth, migration and invasiveness of aggressive cancers in animal models. Using immunohistochemical analyses, we measured the expression of EphA2 in prostatic adenocarcinoma, high-grade prostatic intraepithelial neoplasia, and adjacent benign prostate tissue from ninety-three radical prostatectomy specimens. These results were related to multiple clinical and pathologicalcharacteristics. The fraction of cells staining positively with EphA2 in benign prostatic epithelium (mean, 12%) was significantly lower than that in high-grade prostatic intraepithelial neoplasia (mean, 67%, P < 0.001) and prostatic adenocarcinoma (mean, 85%, P < 0.001). Moreover, the intensity of EphA2 immunoreactivity in prostatic adenocarcinoma was significantly higher than in benign prostatic tissue (P < 0.001) or high-grade prostatic intraepithelial neoplasia (P < 0.001). Benign prostatic epithelium showed weak or no immunoreactivity for EphA2 in all cases examined. Whereas EphA2 immunoreactivity related to neoplastic transformation, it did not correlate with other clinical and pathological parameters examined. Our data suggest that EphA2 levels increase as prostatic epithelial cells progress toward a more aggressive phenotype. Progressively higher levels of EphA2 in high-grade prostatic intraepithelial neoplasia and prostatic carcinoma are consistent with recent evidence that EphA2 functions as a powerful oncogene. Moreover, the presence of high levels of EphA2 in these cells suggests opportunities for prostate cancer prevention and treatment.
This article has been cited by other articles:
 |
|
 |
|
  K. Fizazi The role of Src in prostate cancer Ann. Onc., November 1, 2007; 18(11): 1765 - 1773. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R Holm, S Knopp, Z Suo, C Trope, and J M Nesland Expression of EphA2 and EphrinA-1 in vulvar carcinomas and its relation to prognosis J. Clin. Pathol., October 1, 2007; 60(10): 1086 - 1091. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Parri, F. Buricchi, E. Giannoni, G. Grimaldi, T. Mello, G. Raugei, G. Ramponi, and P. Chiarugi EphrinA1 Activates a Src/Focal Adhesion Kinase-mediated Motility Response Leading to Rho-dependent Actino/Myosin Contractility J. Biol. Chem., July 6, 2007; 282(27): 19619 - 19628. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T L Cibull, T D Jones, L Li, J N Eble, L Ann Baldridge, S R Malott, Y Luo, and L Cheng Overexpression of Pim-1 during progression of prostatic adenocarcinoma. J. Clin. Pathol., March 1, 2006; 59(3): 285 - 288. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Abraham, D. W. Knapp, L. Cheng, P. W. Snyder, S. K. Mittal, D. S. Bangari, M. Kinch, L. Wu, J. Dhariwal, and S. I. Mohammed Expression of EphA2 and Ephrin A-1 in Carcinoma of the Urinary Bladder Clin. Cancer Res., January 15, 2006; 12(2): 353 - 360. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Wykosky, D. M. Gibo, C. Stanton, and W. Debinski EphA2 as a Novel Molecular Marker and Target in Glioblastoma Multiforme Mol. Cancer Res., October 1, 2005; 3(10): 541 - 551. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Cheng, T. D. Jones, R. P. McCarthy, J. N. Eble, M. Wang, G. T. MacLennan, A. Lopez-Beltran, X. J. Yang, M. O. Koch, S. Zhang, et al. Molecular Genetic Evidence for a Common Clonal Origin of Urinary Bladder Small Cell Carcinoma and Coexisting Urothelial Carcinoma Am. J. Pathol., May 1, 2005; 166(5): 1533 - 1539. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. J. Herrem, T. Tatsumi, K. S. Olson, K. Shirai, J. H. Finke, R. M. Bukowski, M. Zhou, A. L. Richmond, I. Derweesh, M. S. Kinch, et al. Expression of EphA2 is Prognostic of Disease-Free Interval and Overall Survival in Surgically Treated Patients with Renal Cell Carcinoma Clin. Cancer Res., January 1, 2005; 11(1): 226 - 231. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Hu, K. L. Carles-Kinch, D. P. Zelinski, and M. S. Kinch EphA2 Induction of Fibronectin Creates a Permissive Microenvironment for Malignant Cells Mol. Cancer Res., October 1, 2004; 2(10): 533 - 540. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Cheng, C.-X. Pan, J.-T. Zhang, S. Zhang, M. S. Kinch, L. Li, L. A. Baldridge, C. Wade, Z. Hu, M. O. Koch, et al. Loss of 14-3-3{sigma} in Prostate Cancer and Its Precursors Clin. Cancer Res., May 1, 2004; 10(9): 3064 - 3068. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
